SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...
There is no Morningstar’s Analysis data available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback